Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. - Wikidata - awgldk - TriplyDB

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

http://www.wikidata.org/entity/Q34043472

about

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease Managing risks in drug discovery: reproducibility of published findings Recent advances in pathogenesis, assessment, and treatment of atherosclerosis From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease The relationship between Lp(a) and CVD outcomes: a systematic review Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction Lipids, blood pressure and kidney update 2015 Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review Low High-Density Lipoprotein and Risk of Myocardial Infarction Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia New developments in atherosclerosis: clinical potential of PCSK9 inhibition PCSK9 inhibition: the way forward in the treatment of dyslipidemia Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents Cardiovascular pharmacogenomics: current status and future directions New drugs for treating dyslipidemia: beyond statins Current therapies for lowering lipoprotein (a)The perils of surrogate endpoints Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders PCSK9 inhibitors in the prevention of cardiovascular disease The year in cardiology 2015: prevention New Era of Lipid-Lowering Drugs PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era A Review of the Key Clinical Trials of 2015: Results and Implications Retargeting the management of hypercholesterolemia - focus on evolocumab Evolocumab Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases PCSK9 inhibitors - clinical applications Lowering cholesterol in chronic kidney disease: is it safe and effective?Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia Immune cell screening of a nanoparticle library improves atherosclerosis therapy Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Lipoprotein(a) in nephrological patients Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

P2860

Q24187425-5B007F1C-D66A-4AB5-A457-D9874FFD3A88 Q24289508-0E514316-353C-45E5-80D3-4C993D3FC2DF Q26740304-0EF8BCA5-4050-4614-96B8-D6DEF2CD1D93 Q26741078-90805820-05E2-4B68-AEFC-F1EA3B23060A Q26747776-CC17BD68-5D82-4C3E-9E49-CF8A4344E18D Q26748869-29B249DE-8B9C-4908-9E02-91210840C6D5 Q26749317-365971D4-50A0-4F59-98DD-96D0BEBFD764 Q26752919-4102EC99-1503-40F3-A879-022F9C81A125 Q26752950-82F3C093-24DA-41BC-BB0E-C42C29782227 Q26771550-F9B16D80-8DDD-4E70-A15D-990997251E02 Q26771862-6442A13C-DA40-4FA3-BB1E-8B4903794C9E Q26773899-3D5071C8-99CC-4E7B-8D90-9C8C2D33D8C8 Q26777184-40AA0624-FAB8-47F8-89EB-B4375E9767A0 Q26783407-B76B0250-110D-4733-8BCE-E297C118FA57 Q26784482-2A3E5D0F-CC04-4D57-858A-AAC27FCC522C Q26786549-5ED119F7-1E2D-40D6-830A-A71B8AD108E6 Q26798119-52CDD786-2876-4FCA-9FAB-9AD6DABB77E7 Q26801183-DA856A37-AAC0-4FD9-A2E5-98BEB2A80B4B Q26821840-5197B89C-8C15-42F9-BC3C-0F320B0DA09C Q26830297-2D89D00A-56A7-4F1D-B376-E194366DB132 Q27025740-03624076-F4F1-4F26-BAB1-367B672EE4D4 Q27339783-4E71C82A-A22A-4977-8006-7EC627FDDD43 Q28070296-671C46F2-07A2-42FB-A887-10BDAD253F16 Q28071452-8D5805DC-40F7-4797-8DB1-46962E6B1C3F Q28072221-1F14FF8D-D687-4408-998D-5DD7AC2A9D9C Q28072298-8121BFD0-971D-4518-966C-30658E8338EF Q28073656-5FEB3E7E-832C-43C3-864E-A67BBD4BDDA2 Q28077170-488BD929-2B87-4DCB-A003-E8EC5CA4039C Q28077289-D6FFCA49-DAC0-4C1F-BEBC-A36332840867 Q28078902-CBB8AAAF-A45E-41FE-9357-36DEB1D5AD36 Q28079294-06535C22-0300-4756-9D5E-56A589244986 Q28079757-4DBCB504-D46B-4F56-9AD3-B097F5A20636 Q28083502-DAA4DE34-FA70-4BB6-AA52-643FFD3471CD Q28084156-81DE3046-8033-4EBC-A2F3-94C744E75B76 Q28275648-237EEB34-1392-40F9-AED1-65F807E9580D Q28393434-3A465D25-5BD2-4E00-B76A-C93EA595EF52 Q29994487-C4D1E910-9ED4-45DA-8E5A-C52605A3A35D Q30234612-CADEE635-285D-4363-8C5A-A8895C70FDB8 Q30236043-B8B2920A-9B15-4476-98BB-2C9A4D682057 Q30244599-F1D15FB4-7357-4105-8180-789D2FD067F6

P2860

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

http://www.wikidata.org/entity/Q34043472

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@nl

type

label

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@nl

prefLabel

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@nl

P1433

Q34043472-7D21F2D5-9A38-4ABF-A528-DE65C5AB5D85

P1476

Q34043472-E78D05A3-2CA3-4B7F-A8E0-E8B0EEDC50D6

P2093

Q34043472-16EE7453-E079-40C3-8B1D-DB471DDD1572

Q34043472-22309EC5-B698-42EA-9D6B-EDF80C73A576

Q34043472-5AB0AD0E-5F60-493E-A3A7-04D0D56D6877

Q34043472-5B3C58F8-669B-4086-9666-8BF535A4AB36

Q34043472-7ACF5243-7AC7-48E1-9EAD-479B300C53A2

Q34043472-981D5106-275F-4C58-BB72-BA24B66217D8

Q34043472-A553503B-3D55-4F5B-96E6-1DE8252FDD88

Q34043472-A751E3E4-817F-44FD-847C-DEF004D2031D

Q34043472-B9FBC4AB-F12D-4494-BD1F-673CBEAD2859

Q34043472-D9B7B392-6BD9-422A-B4FE-768D0FC31018

P304

Q34043472-7588EB89-1127-4882-B935-85F5DC276821

P31

Q34043472-D7E3CC79-1BBB-4162-AA8A-56C03C95FD93

P356

Q34043472-7ABAC510-5939-4676-B099-51C63DCCBED9

P407

Q34043472-ED8CC6E3-7918-4925-934D-83CD274405C8

P433

Q34043472-2539F5A8-3F7C-47F5-AF6C-127612E9D88F

P478

Q34043472-29ECC96F-EF7D-4181-998E-F3236623B5AF

P50

Q34043472-7490472A-5896-44A0-9C1C-627A59A7594E

Q34043472-E5D22BE5-1C2E-41CE-AA1D-133857E3D970

Q34043472-EA550E32-6BE7-4628-A58A-9174FFC83C7D

P577

Q34043472-F1EA64C0-DFDF-477F-9313-D2CE9C4259B3

P698

Q34043472-4241A382-2A9D-4B26-A1ED-95A72AB9ACBD

P921

Q34043472-6D79B0C5-58A0-4374-A3F8-622ABB5CB6E2

P356

P1433

The New England Journal of Medicine

P1476

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

@en

P2093

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

Evan A Stein

http://www.w3.org/2001/XMLSchema#string

Frederick J Raal

http://www.w3.org/2001/XMLSchema#string

Jason Legg

http://www.w3.org/2001/XMLSchema#string

Jennifer Robinson

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

Michael J Koren

http://www.w3.org/2001/XMLSchema#string

Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators

http://www.w3.org/2001/XMLSchema#string

Ransi Somaratne

http://www.w3.org/2001/XMLSchema#string

Scott M Wasserman

http://www.w3.org/2001/XMLSchema#string

P304

1500-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1500858

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Robert P Giugliano

P577

2015-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25773607

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio